Montagnon B J, Fanget B, Nicolas A J
Dev Biol Stand. 1981;47:55-64.
As the increasing shortage of monkeys is a reality, the application of an alternative cell substrate for large-scale production of Killed Poliomyelitis Vaccine (KPV) was studied. Through progress of scientific knowledge the non-tumorigenic VERO cell line was considered to be a suitable alternative cell substrate for this purpose. The Master-Cell-Bank and Working-Cell-Banks prepared by us are giving a practically inexhaustible cell source. Using micro-carrier culture, weekly more than 400 billions of cells at a concentration of 10(6) cells per ml could be obtained for virus inoculation. The virus yield per cell was at least as high as for primary monkey kidney cells. Processing of virus harvests could be performed according to the methods used at the production on primary monkey kidney cells. From a technological view-point large-scale production of KPV on VERO cells appears to be possible economically. More research on the safety control might be necessary.
由于猴子日益短缺是一个现实情况,因此研究了使用替代细胞基质大规模生产脊髓灰质炎灭活疫苗(KPV)。随着科学知识的进步,非致瘤性VERO细胞系被认为是用于此目的的合适替代细胞基质。我们制备的主细胞库和工作细胞库提供了几乎取之不尽的细胞来源。使用微载体培养,每周可获得超过4000亿个浓度为每毫升10(6)个细胞的细胞用于病毒接种。每个细胞的病毒产量至少与原代猴肾细胞一样高。病毒收获物的处理可以按照原代猴肾细胞生产中使用的方法进行。从技术角度来看,在VERO细胞上大规模生产KPV在经济上似乎是可行的。可能需要对安全控制进行更多研究。